Abstract
Tuberculosis (TB) remains to be a leading infectious cause of death Worldwide. Apparently, the current BCG vaccine that has been used for 80 years, has failed to control the TB epidemic. Hunting for improved TB vaccine formulations represents a daunting task to TB research community. Anti-TB host Defense requires T cell-mediated immunity and we are in desperate need of enhanced understanding of how to develop a new generation of TB vaccines that are able to provoke potent and long-lasting protective cell-mediated immunity, different from almost all of the vaccines currently in use. It is of importance to successful TB vaccine development to identify the key cellular and molecular events governing the generation of anti-TB immunity, but unfortunately little has been understood as to why 90percent of infected humans never develop active TB. However, waiting would not help us to win the battle and an ever-intensifying effort is being made to develop various new formulations according to the immunology that we have been learning, in large part, from experimental models. This review article attempts to unite the current understanding of anti-TB immunity with the rational design of anti-TB vaccines. It examines what may have confounded the immunogenicity of current BCG vaccine and the major obstacles to successful development of TB vaccines. It also discusses about antigen presentation, activation of Th1 and Tc1 cells, anti-TB immune effectors and the generation of memory T cells. The vaccine section describes four types of major TB vaccines under development: mycobacterial-, subunit-, plasmid DNA- and viral-based vaccines. A special section is dedicated to the rationale and current design of cytokine-based adjuvant formulations for TB vaccines. We also take this opportunity to introduce our recent development in cytokine transgene adjuvanted BCG vaccination and recombinant Adenoviral-based TB vaccines.
Keywords: Tuberculosis Vaccines, Anti-TB Immunity, TB immunity, BCG VACCINE, Dendritic Cells, MHC Class, Mycobacterial-based Vaccines, Recombinant BCG, Auxotrophic Mutants, Subunit-based Vaccines
Current Pharmaceutical Design
Title: The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines
Volume: 7 Issue: 11
Author(s): Zhou Xing
Affiliation:
Keywords: Tuberculosis Vaccines, Anti-TB Immunity, TB immunity, BCG VACCINE, Dendritic Cells, MHC Class, Mycobacterial-based Vaccines, Recombinant BCG, Auxotrophic Mutants, Subunit-based Vaccines
Abstract: Tuberculosis (TB) remains to be a leading infectious cause of death Worldwide. Apparently, the current BCG vaccine that has been used for 80 years, has failed to control the TB epidemic. Hunting for improved TB vaccine formulations represents a daunting task to TB research community. Anti-TB host Defense requires T cell-mediated immunity and we are in desperate need of enhanced understanding of how to develop a new generation of TB vaccines that are able to provoke potent and long-lasting protective cell-mediated immunity, different from almost all of the vaccines currently in use. It is of importance to successful TB vaccine development to identify the key cellular and molecular events governing the generation of anti-TB immunity, but unfortunately little has been understood as to why 90percent of infected humans never develop active TB. However, waiting would not help us to win the battle and an ever-intensifying effort is being made to develop various new formulations according to the immunology that we have been learning, in large part, from experimental models. This review article attempts to unite the current understanding of anti-TB immunity with the rational design of anti-TB vaccines. It examines what may have confounded the immunogenicity of current BCG vaccine and the major obstacles to successful development of TB vaccines. It also discusses about antigen presentation, activation of Th1 and Tc1 cells, anti-TB immune effectors and the generation of memory T cells. The vaccine section describes four types of major TB vaccines under development: mycobacterial-, subunit-, plasmid DNA- and viral-based vaccines. A special section is dedicated to the rationale and current design of cytokine-based adjuvant formulations for TB vaccines. We also take this opportunity to introduce our recent development in cytokine transgene adjuvanted BCG vaccination and recombinant Adenoviral-based TB vaccines.
Export Options
About this article
Cite this article as:
Xing Zhou, The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines, Current Pharmaceutical Design 2001; 7 (11) . https://dx.doi.org/10.2174/1381612013397636
DOI https://dx.doi.org/10.2174/1381612013397636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chest X-ray in Sarcoidosis: The Association of Age, Gender, and Ethnicity with Different Radiological Findings
Current Respiratory Medicine Reviews Evaluation of Risk Factors for Development of Anti-Tubercular Therapy Induced Hepatotoxicity: A Prospective Study
Current Drug Safety Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry An Environmentally Friendly, Scalable and Highly Efficient Synthesis of (S,S)-Ethambutol, a First Line Drug against Tuberculosis
Letters in Organic Chemistry Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis
Recent Patents on Anti-Infective Drug Discovery Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine New Plates for Different Types of Plate Heat Exchangers
Recent Patents on Mechanical Engineering Histopathological Scores for Tissue-Engineered, Repaired and Degenerated Tendon: A Systematic Review of the Literature
Current Stem Cell Research & Therapy Design of Novel Phosphopantetheine Adenylyltransferase Inhibitors: A Potential New Approach to Tackle <i>Mycobacterium tuberculosis</i>
Current Topics in Medicinal Chemistry Seco-Tetracyclic and Seco-Pentacyclic Triterpenoids from Nature: Phytochemistry, Biological Activity: A Review
Mini-Reviews in Organic Chemistry An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology A Review of Flavonoids from Cassia Species and their Biological Activity
Current Pharmaceutical Biotechnology A Review of Computational Identification of Protein Post-Translational Modifications
Mini-Reviews in Organic Chemistry Use of Guanidine Compounds in the Treatment of Neglected Tropical Diseases
Current Organic Chemistry Synthesis of Imidazo[1,2-b]pyridazine Comprised Piperazine, Morpholine Derivatives as Potent Antimycobacterial Agents with In Vivo Locomotor Activity
Anti-Infective Agents New Insights on the Nature of Latent Tuberculosis Infection and its Treatment
Inflammation & Allergy - Drug Targets (Discontinued) Clostridium difficile Infection in Children with Inflammatory Bowel Disease: Current Evidence
Current Pharmaceutical Design Emergence of Heteroresistance Mycobacterium Tuberculosis in Saudi Arabia
Infectious Disorders - Drug Targets